According to Figure 2 and Table 3, the results of the network meta-analysis for different safety events are described (refer to the presentation format for Grade 3 or higher TRAEs).
Grade 3 or Higher TRAEs: Compared to chemotherapy, only Dato-DXd showed a significantly lower incidence of Grade 3 or higher TRAEs, while the incidence of SG was significantly higher. Compared to other Trop2-ADCs, Dato-DXd had a significantly lower incidence of Grade 3 or higher TRAEs (compared to SKB264: OR = 0.326, 95% CI: 0.181-0.587; compared to SG: OR = 0.165, 95% CI: 0.1-0.268). The probability ranking results show that Dato-DXd ranks first with a SUCRA of 1.000, followed by chemotherapy, SKB264, and SG.
TRAE Ranking Order:
- Overall TRAEs: Chemotherapy, Dato-DXd, SG, and SKB264.
- TRAEs leading to discontinuation: SKB264, chemotherapy, and Dato-DXd.
- TRAEs leading to death: Dato-DXd, chemotherapy, SKB264, and SG.
- SAEs: Dato-DXd, chemotherapy, SKB264, and SG.
Hematological Toxicity: For Grade 3 or higher anemia, leukopenia, and neutropenia, Dato-DXd ranked first. SKB264 ranked fourth in anemia and second in leukopenia and neutropenia.
Non-hematological Toxicity:
- Grade 3 or higher stomatitis: Chemotherapy, Dato-DXd, and SKB264.
- Grade 3 or higher fatigue and constipation: Dato-DXd ranked better than SG.
- Grade 3 or higher nausea, vomiting, and alopecia: Dato-DXd ranked worse than SG.
- Elevated transaminases and other rankings indicate that SG has better safety than SKB264.
